Childhood cancers are rare, but incidence has risen modestly in countries with robust registration, partly reflecting improved diagnosis. In high-income countries, cancer is the leading cause of disease-related death in children. Marked inequities in incidence, survival, and research capacity underscore the need for large-scale collaboration to identify environmental, genetic, and contextual determinants of risk. The Childhood Cancer and Leukemia International Consortium (CLIC) was established in 2007 to study the etiology of childhood leukemia and later expanded in 2019 to include other childhood cancers, principally solid tumors. CLIC pools harmonized, individual-level data from case–control and cohort studies, obtained through interviews, record linkage (insurance claims, registries), or geographic information systems, and integrates germline genomic data where available. Membership has grown from 13 studies in 9 countries to 57 studies in 21 countries; recruitment spans the early 1960s to the present and encompasses approximately 150,000 cases across all tumor types and 300,000 controls with clinical, demographic, and exposure data, centralized via harmonized data dictionaries at the Data Coordination Center, established in 2014 at the International Agency for Research on Cancer, and supported by a secure analysis platform. Pooled analyses across diverse populations have implicated parental age, prenatal vitamin or folic acid use, mode of delivery, fetal growth, selected congenital anomalies, occupational or household exposures (e.g., pesticides), paternal smoking, and markers of early-life immune modulation (e.g., breastfeeding, daycare attendance) in leukemia risk, informing carcinogen evaluation and prevention. The integration of genetic ancestry and germline susceptibility data is clarifying ancestry-related differences in leukemia biology and outcomes, while confirming risk loci with population-specific effects. CLIC is now adding polygenic risk scores and exposomic data to refine etiologic subtyping and identify modifiable pathways, while broadening representation from underserved regions through partnership-building and capacity-strengthening.
Ana M. Mora, J. Mejía-Aranguré, J. Dockerty et al.· Cancer Epidemiology· 0 citations
BACKGROUND
The association between vitamin B12 deficiency and colorectal cancer (CRC) risk remains uncertain. We evaluated the association between low serum vitamin B12 concentration (<200 pg/mL) and CRC incidence and all-cause mortality, using a midrange reference group (400-600 pg/mL).
METHODS
In this retrospective propensity score-matched cohort study, adults with serum B12 measurements between 2006 and 2020 were identified from the TriNetX Global Collaborative Network. Patients with any neoplasm diagnosis within 5 years before the index date (first B12 measurement) were excluded. Patients with B12 <200 pg/mL were matched 1:1 to those with 400-600 pg/mL and followed for up to 10 years. Time-stratified, landmark, subgroup, E-value, and outcome-control analyses were performed.
RESULTS
After matching, 184,126 pairs were included. Low serum B12 was associated with higher CRC risk (HR 1.16; 95% CI, 1.09-1.23) and all-cause mortality (HR 1.16; 95% CI, 1.14-1.18). The CRC association persisted at the 2-year landmark (HR 1.16; 95% CI, 1.07-1.26) but attenuated at the 3-year (HR 1.07; 95% CI, 0.98-1.18) and 5-year (HR 1.12; 95% CI, 0.99-1.25) landmarks, whereas all-cause mortality remained elevated across all landmarks. The appendicitis negative control was null (HR 0.92; 95% CI, 0.84-1.02), whereas clavicle fracture was weakly positive (HR 1.08; 95% CI, 1.01-1.16).
CONCLUSIONS
Low serum vitamin B12 was associated with higher all-cause mortality; its association with CRC was less robust at longer landmarks.
IMPACT
The mortality association was more robust; the CRC finding requires prospective confirmation with serial B12 measurements.
Yuan-Tsung Tseng, Kow-Tong Chen, Pei-Chen Lee et al.· Cancer Epidemiology, Biomark...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.